淄博齐翔腾达化工股份有限公司 2025 年第一季度报告 淄博齐翔腾达化工股份有限公司 2025 年第一季度报告 债券代码：128128 债券简称：齐翔转 2 证券代码：002408 证券简称：齐翔腾达 公告编号：2025-027 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | （%） | | | 营业收入（元） | 5,618,126,945.15 | 5,479,652,158.91 | | 2.53% | | 归属于上市公司股东的净利 | 5,400, ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥3,416,263,841.99, representing a 15.05% increase compared to ¥2,969,367,795.11 in the same period last year[5] - Net profit attributable to shareholders for Q1 2025 was ¥212,363,345.15, up 10.89% from ¥191,504,960.60 in the previous year[5] - Basic earnings per share increased to ¥0.26, an 8.33% rise from ¥0.24 in the same period last year[5] - Net profit for the current period was ¥238,101,581.55, representing a growth of 12.8% from ¥210,953,710.43 in the previous period[18] - The net profit attributable to the parent company was ¥212,363,345.15, an increase of 10.9% compared to ¥191,504,960.60 last year[18] - The company reported a total comprehensive income of ¥260,724,757.44, compared to ¥196,721,841.41 in the previous period, indicating a growth of 32.6%[18] Cash Flow - The net cash flow from operating activities improved significantly, reaching -¥135,238,381.45, a 78.80% increase from -¥637,938,327.47 year-on-year[5] - Net cash inflow from operating activities was CNY 2,429,528,205.71, an increase from CNY 1,979,571,077.08 year-over-year[21] - Net cash outflow from operating activities was CNY 2,564,766,587.16, compared to CNY 2,617,509,404.55 in the previous year[21] - Cash inflow from financing activities totaled CNY 1,845,924,936.53, up from CNY 1,158,335,519.64 in the previous year[22] - The net increase in cash and cash equivalents was CNY 116,953,375.31, contrasting with a decrease of CNY 165,557,279.14 in the previous year[22] - The ending balance of cash and cash equivalents was CNY 1,870,683,397.35, compared to CNY 1,412,427,963.08 at the end of the previous year[22] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥19,205,731,972.75, a 4.59% increase from ¥18,362,138,756.84 at the end of the previous year[5] - Total liabilities increased to ¥11,840,640,465.66, up from ¥11,290,344,646.41, reflecting a growth of 4.9%[14] - Total equity rose to ¥7,365,091,507.09, compared to ¥7,071,794,110.43, marking an increase of 4.1%[14] - The total current assets amount to ¥12,182,483,457.27, an increase from ¥11,493,504,083.49 at the beginning of the period, representing a growth of approximately 6.0%[13] - The total non-current assets are valued at ¥7,023,248,515.48, up from ¥6,868,634,673.35, indicating a growth of approximately 2.3%[13] - Short-term borrowings increased to ¥2,607,297,435.97 from ¥2,063,530,858.32, representing a significant increase of about 26.4%[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 50,697[10] - The largest shareholder, Xu Xiaomin, holds 6.66% of shares, totaling 55,615,820 shares[10] - The company has no preferred shareholders as indicated in the report[11] Expenses - Total operating costs amounted to ¥3,131,333,531.61, up 14.3% from ¥2,738,214,542.52 in the prior period[16] - Research and development expenses were ¥136,756,160.11, slightly down from ¥136,840,304.13 in the prior period[17] - The company reported a significant decrease in financial expenses, down 87.42% to ¥3,331,273.87 from ¥26,475,702.80 year-on-year[8] Investment Income - Investment income for the period was ¥5,299,297.95, a substantial increase of 114.05% compared to ¥2,475,703.75 in the previous year[8] - Cash received from investment recoveries was CNY 526,753,052.04, significantly higher than CNY 196,167,745.48 in the previous year[21]

瑞康医药集团股份有限公司 2025 年第一季度报告 证券代码：002589 证券简称：瑞康医药 公告编号：2025-024 瑞康医药集团股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 否 1 适用 □不适用 | 项目 | 本报告期金额 | 说明 | | --- | --- | --- | | 非流动性资产处置损益（包括已 | 5,015,126.92 | | | 计提资产减值准备的冲销部分） | | | | 计入当期损益的政府补助（与公 司正常经营业务密切相关、符合 | | | | 国家政策规定、按照确定的标准 | 215,831.84 | | | 享有、对公司损益产生持续影响 | | | | 的政府补助除外） ...

深圳市拓日新能源科技股份有限公司 2025 年第一季度报告 证券代码：002218 证券简称：拓日新能 公告编号：2025-019 一、主要财务数据 （一） 主要会计数据和财务指标 深圳市拓日新能源科技股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 253,675,644.48 | 283,472,465.38 | -10.51% | | 归属于上市公司股东的净利润 | -40,814,435. ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥16,072,114,131.47, a decrease of 10.78% compared to ¥18,013,873,383.09 in the same period last year[5] - Net profit attributable to shareholders increased by 14.07% to ¥273,025,334.39 from ¥239,349,144.22 year-on-year[5] - Basic earnings per share rose by 16.67% to ¥0.07 from ¥0.06 year-on-year[5] - Operating profit for the period was CNY 366,995,499.08, down 7.8% from CNY 398,140,234.13 in the prior year[30] - The company reported a decrease in total operating costs to CNY 15,771,314,358.22, down 10.5% from CNY 17,623,749,487.39 in the previous year[29] Cash Flow - The net cash flow from operating activities was negative at -¥281,646,956.12, a significant decline of 188.22% compared to ¥319,240,283.61 in the previous year[5] - Cash flow from operating activities showed a net outflow of CNY 281,646,956.12, compared to a net inflow of CNY 319,240,283.61 in the same period last year[31] - In Q1 2025, the net cash flow from financing activities was CNY 1,373,573,129.84, an increase of 48.3% compared to CNY 926,837,303.76 in the same period last year[32] - The net increase in cash and cash equivalents for the quarter was CNY 655,423,987.17, down from CNY 896,136,639.57 in the previous year[32] - The ending balance of cash and cash equivalents was CNY 3,087,771,816.72, a decrease from CNY 3,762,907,297.07 year-over-year[32] Assets and Liabilities - Total assets increased by 5.76% to ¥48,478,437,037.96 from ¥45,836,502,702.57 at the end of the previous year[5] - As of March 31, 2025, the company's total assets reached RMB 48.48 billion, an increase from RMB 45.84 billion at the beginning of the period[27] - The company's total liabilities amounted to RMB 30.61 billion, compared to RMB 28.25 billion at the beginning of the period[27] - The company's current assets totaled RMB 20.55 billion, up from RMB 18.22 billion at the beginning of the period[26] - The company's inventory rose to RMB 12.99 billion, compared to RMB 11.76 billion at the beginning of the period[26] Investments and Acquisitions - The company agreed to introduce three financial investors with a total investment of RMB 1.11 billion, increasing registered capital to RMB 3 billion[14] - The company has completed the acquisition of overseas convertible bond debts, with a minimum purchase price of RMB 504,440,664.09[17] - The company plans to invest up to RMB 1.94 billion in debt and equity recovery with asset management companies[14] - The company has signed agreements to acquire trust rights held by China Galaxy Asset Management Co., Ltd. for RMB 85,371,900.00[18] - The company acquired 64% of Shandong Zhongjin New Materials Technology Co., Ltd. through capital increase, with a valuation of RMB 99.5 million as of November 30, 2024[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 127,696[12] - Guangdong Guangsheng Holding Group Co., Ltd. holds 34.90% of shares, totaling 1,304,407,036 shares[12] Restructuring and Management - The company participated in the bankruptcy reorganization of 20 companies, including Dongying Fangyuan Nonferrous Metals Co., Ltd.[13] - The company has officially taken over the restructured enterprises and is managing production operations related to copper smelting[15] - The company completed the restructuring plan confirmed by the Dongying Intermediate People's Court, ending the restructuring procedures for 20 companies, including Dongying Fangyuan Nonferrous Metals Co., Ltd.[20]

Financial Performance - The company's operating revenue for Q1 2025 was ¥415,442,391.09, a decrease of 7.91% compared to ¥451,143,419.42 in the same period last year[4] - The net loss attributable to shareholders was ¥110,862,966.88, representing a 10.23% increase in loss from ¥100,574,100.54 year-on-year[4] - Net profit for the current period is -$113.93 million, compared to -$100.70 million in the previous period, indicating a worsening performance[18] - The company’s weighted average return on equity was -2.55%, a decrease of 0.62% from -1.93% in the previous year[4] - Basic and diluted earnings per share are both -$0.10, compared to -$0.09 in the previous period, indicating a decline in profitability[18] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥40,471,089.83, a 72.75% reduction from the previous year's outflow of ¥148,496,630.23[4] - Cash and cash equivalents significantly increased to CNY 822,536,383.45 from CNY 290,411,351.19, representing a growth of over 184%[13] - Cash and cash equivalents at the end of the period increased to $822.53 million, up from $159.06 million in the previous period[22] - The company reported a significant increase in cash received from financing activities, totaling ¥648,342,260.38, a 1323.91% increase compared to ¥45,532,646.05 in the previous period[8] - Financing activities generated a net cash inflow of $648.34 million, significantly higher than $45.53 million in the previous period[22] Assets and Liabilities - Total assets increased by 4.32% to ¥10,790,829,064.25 from ¥10,344,170,810.30 at the end of the previous year[4] - Current assets increased to CNY 2,690,285,494.42 from CNY 2,134,710,887.26, reflecting a growth of approximately 26%[13] - Total liabilities rose to CNY 6,494,720,187.13, compared to CNY 5,934,371,375.74, indicating an increase of about 9%[14] - The company’s equity attributable to shareholders decreased to CNY 4,290,636,051.49 from CNY 4,401,262,829.96, a decline of approximately 2.5%[14] - The total non-current liabilities increased to CNY 1,455,948,241.59 from CNY 344,679,603.31, indicating a significant rise[14] Investment and Research Activities - The company reported a significant decrease in cash received from investment activities, down 98.89% to ¥1,400,000.00 from ¥125,707,638.44 in the previous year[8] - Investment activities resulted in a net cash outflow of -$73.63 million, compared to -$52.83 million in the previous period[21] - Research and development expenses decreased to $13.33 million, down from $15.91 million in the previous period, reflecting a 16.2% reduction[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 103,526, with no preferred shareholders[10] - The company reported a total of 109,880,373 shares held by Hubei Chutian Digital Television Co., Ltd., the largest shareholder[12] Other Information - The company has not disclosed any new product developments or market expansion strategies during the reporting period[12]

Financial Performance - The company's revenue for Q1 2025 was CNY 616,290,632.44, representing a 1.63% increase compared to CNY 606,418,745.97 in the same period last year[5]. - Net profit attributable to shareholders increased by 35.47% to CNY 15,756,417.46 from CNY 11,631,055.35 year-on-year[5]. - The net profit after deducting non-recurring gains and losses surged by 124.92% to CNY 14,859,606.87 compared to CNY 6,606,701.04 in the previous year[5]. - The basic earnings per share increased by 35.71% to CNY 0.0209 from CNY 0.0154 in the previous year[5]. - Net profit for the current period was ¥18,569,461.39, up from ¥12,221,608.41 in the previous period, indicating a growth of approximately 52.1%[41]. - The company reported a basic and diluted earnings per share of ¥0.0209, compared to ¥0.0154 in the previous period, marking an increase of 35.7%[42]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 3,763,967,569.81, a 1.40% increase from CNY 3,712,072,946.95 at the end of the previous year[5]. - Total current assets increased to ¥1,694,347,602.60 from ¥1,608,572,076.75, showing a growth of about 5.34%[37]. - Total liabilities rose to ¥1,938,376,781.22 from ¥1,905,075,191.42, reflecting an increase of approximately 1.73%[38]. - Non-current assets decreased slightly to ¥2,069,619,967.21 from ¥2,103,500,870.20, a decline of about 1.61%[37]. - The company’s total equity increased to ¥1,825,590,788.59 from ¥1,806,997,755.53, reflecting a growth of about 1.03%[38]. Cash Flow - The net cash flow from operating activities decreased by 13.08% to CNY 65,817,386.44 from CNY 75,724,156.95 year-on-year[5]. - Operating cash inflow for the current period was CNY 661,698,263.65, an increase of 3.1% from CNY 638,384,479.19 in the previous period[43]. - Net cash flow from operating activities decreased to CNY 65,817,386.44, down 13.1% from CNY 75,724,156.95 in the previous period[43]. - Cash outflow from investment activities was CNY 27,129,815.36, a decrease of 13.5% compared to CNY 31,481,850.94 in the previous period[44]. - Net cash flow from financing activities improved to CNY 8,349,308.14, compared to a net outflow of CNY 19,602,920.60 in the previous period[44]. - The net increase in cash and cash equivalents for the current period was CNY 47,549,946.22, up 92.1% from CNY 24,702,423.76 in the previous period[44]. - The ending balance of cash and cash equivalents was CNY 186,333,958.00, down from CNY 210,575,158.90 in the previous period[44]. Shareholder Information - The company reported a total of 70,713 common shareholders at the end of the reporting period[12]. - The largest unrestricted shareholders are Gome Holdings Group Co., Ltd. with 186,113,207 shares and Gome Electrical Appliances Co., Ltd. with 50,807,055 shares[13]. - Gome Holdings Group's frozen shares include 12,500,000 shares judicially frozen, 110,403,529 shares judicially re-frozen, and 59,562,814 shares under pending freeze[14]. - Gome Holdings Group Co., Ltd. holds 186,113,207 shares, representing 24.71% of total shares[21]. - Gome Electrical Appliances Co., Ltd. holds 50,807,055 shares, representing 6.75% of total shares[21]. - A total of 236,920,262 shares are held by major shareholders, accounting for 31.46% of total shares[21]. - Gome Holdings has pledged 111,601,400 shares, which is 59.96% of its holdings[21]. - Gome Holdings has 122,903,529 shares under judicial freeze, representing 66.04% of its holdings[22]. - Gome Electrical Appliances has 50,807,055 shares under judicial freeze, accounting for 100% of its holdings[22]. Corporate Governance - The company held its first temporary shareholders' meeting on January 23, 2025, to elect the ninth board of directors and supervisory board[16]. - The ninth board of directors consists of 6 non-independent directors and 3 independent directors, with Xu Zhongmin as the chairman[17]. - The audit committee is chaired by Bi Ke, a professional accountant, with members including Huang Xiuhong, Shi Lu Wen, and Xia Qin[17]. - The company appointed Hou Zhanjun as the president and several others as vice presidents, with their terms aligned with the current board[17]. - Lin Feiyan has terminated the concerted action agreement with Gome Holdings and Gome Electrical Appliances[19]. - The shareholding ratio of the controlling shareholder and its concerted parties changed following the termination of the agreement[19]. Subsidiary Developments - The company’s subsidiary, Beijing Huasu Pharmaceutical, received acceptance for the consistency evaluation of Tramadol Hydrochloride Tablets[24]. - The company’s subsidiary, Duoduo Pharmaceutical, won the bid for the national centralized procurement of Siberian Ginseng Injection at a price of 13.18 yuan per unit[25]. - The procurement cycle for the selected product is from the execution date until December 31, 2027[25]. - Beijing Huasu Pharmaceutical's raw material drug, Benzydamine, has received the production license and passed the GMP compliance inspection, indicating it meets current drug management standards and can ensure patient safety[27][28][29]. - Beijing Zhongshi New Materials has been awarded the High-tech Enterprise Certificate, valid for three years, allowing it to benefit from a 15% corporate income tax rate from 2024 to 2026[30]. - Shandong Huasu Health Care Products has also received the High-tech Enterprise Certificate, which is expected to positively impact the company's performance in 2024[31]. - Beijing Huasu's application for the marketing license of Oxycodone Hydrochloride Controlled-release Tablets (40mg) has been accepted, marking the start of the review phase[32][33]. - Duoduo Pharmaceutical's application for the marketing license of Bromhexine Hydrochloride Injection (2ml:4mg) has been accepted, indicating progress in the development of respiratory medications[34]. Operational Efficiency - The company has optimized its production structure and expanded its product range, enhancing its core competitiveness and meeting market demand[29]. - The acceptance of multiple drug applications is expected to enhance the company's market competitiveness and positively impact its financial performance[33][34]. Other Financial Metrics - Total operating revenue for the current period reached ¥616,290,632.44, an increase from ¥606,418,745.97 in the previous period, representing a growth of approximately 1.43%[40]. - Total operating costs decreased to ¥591,018,803.44 from ¥594,281,237.26, reflecting a reduction of about 0.38%[40]. - Research and development expenses were reported at ¥16,977,265.67, down from ¥22,994,485.44, indicating a decrease of approximately 26%[41]. - The company’s cash and cash equivalents were not explicitly detailed, but the increase in current assets suggests improved liquidity[37]. - The company’s first quarter report was not audited[46].

Financial Performance - The company's operating revenue for Q1 2025 was ¥760,588,639.34, a decrease of 42.93% compared to ¥1,332,744,270.05 in the same period last year[5] - Net profit attributable to shareholders was ¥24,169,730.06, down 53.25% from ¥51,695,103.14 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥1,595,976.79, a significant decline of 96.42% compared to ¥44,605,736.36 in the previous year[5] - Basic and diluted earnings per share were both ¥0.02, reflecting a 50.00% decrease from ¥0.04 in the previous year[5] - Net profit for the current period is ¥24,305,694.00, representing a decline of 52.4% from ¥51,074,838.51 in the previous period[18] - Earnings per share (basic and diluted) is ¥0.02, down from ¥0.04 in the previous period[19] Cash Flow - The net cash flow from operating activities improved to ¥102,624,994.29, a 140.30% increase from a negative cash flow of ¥254,664,208.38 in the same period last year[5] - The net cash flow from operating activities was $102.62 million, a significant improvement compared to a net outflow of $254.66 million in the previous period[21] - Total cash outflow from operating activities amounted to $662.47 million, down from $1.04 billion year-over-year[21] - Cash inflow from financing activities was $619.20 million, compared to $541.07 million in the previous period[21] - Cash outflow for employee compensation was $148.98 million, a decrease from $175.70 million year-over-year[21] - Cash paid for taxes was $78.34 million, down from $114.61 million in the previous period[21] - Cash paid for other operating activities was $252.89 million, reduced from $388.93 million year-over-year[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,055,820,136.30, a decrease of 1.11% from ¥7,134,925,658.08 at the end of the previous year[5] - Total current liabilities decreased to ¥3,590,445,962.43 from ¥3,799,824,847.07, a reduction of about 5.5%[14] - Total liabilities amount to ¥3,832,313,151.24, a decrease from ¥3,935,723,314.43 in the previous period[15] - Total non-current assets are valued at ¥3,470,342,343.27, down from ¥3,491,289,386.18, a decrease of approximately 0.6%[14] Research and Development - The company's R&D expenses increased by 168.83% to ¥8,118,990.09, compared to ¥3,020,082.42 in the same period last year, indicating a focus on innovation[8] - Research and development expenses increased to ¥8,118,990.09, up 168.5% from ¥3,020,082.42 in the previous period[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 80,863[10] - The largest shareholder, Jiang Wei, holds 17.55% of shares, with 245,346,284 shares pledged[10] - The company has a total of 32,588,712 shares held in the repurchase special account, representing 2.33% of total shares[11] - The company has not reported any significant changes in the top 10 shareholders due to margin trading or lending of shares[11] Other Income and Expenses - Other income surged by 672.31% to ¥35,739,844.30, up from ¥4,627,661.00 year-on-year, primarily due to increased government subsidies received by subsidiaries[8] - The company reported a net loss from investment of ¥7,736,280.49, compared to a loss of ¥5,833,183.59 in the previous period[18] - Cash inflow from operating activities totaled ¥765,095,329.13, slightly down from ¥783,207,961.75 last year[20] Accounting and Auditing - The company did not undergo an audit for the first quarter report[22] - The company plans to implement new accounting standards starting in 2025[22]

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,020,227,838.27, a decrease of 7.79% compared to ¥1,106,366,984.18 in the same period last year[4] - Net profit attributable to shareholders increased by 210.36% to ¥97,458,424.85 from ¥31,401,651.30 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 151.37% to ¥75,114,424.89 compared to ¥29,881,476.41 in the previous year[4] - Basic and diluted earnings per share increased by 209.93% to ¥0.0936 from ¥0.0302 year-on-year[4] - The net profit for the current period is CNY 102,512,095.70, a significant increase from CNY 36,539,562.59 in the previous period, representing a growth of approximately 180%[22] - Operating profit reached CNY 103,601,008.43, compared to CNY 28,122,288.44 in the prior period, indicating an increase of about 268%[22] - The total comprehensive income for the current period was CNY 102,837,588.61, compared to CNY 39,576,509.49 in the previous period, an increase of about 160%[22] - The company's total profit for the current period was CNY 103,326,409.46, significantly higher than CNY 27,989,540.54 in the previous period, representing an increase of approximately 269%[22] Cash Flow and Assets - The net cash flow from operating activities decreased by 127.92%, resulting in a negative cash flow of ¥51,088,750.96, down from ¥182,981,156.57 in the same period last year[4] - As of March 31, 2025, the company's cash and cash equivalents amount to RMB 1,207,276,563.47, an increase from RMB 1,090,277,256.71 at the beginning of the period[18] - Cash flow from investment activities generated a net inflow of CNY 212,830,668.01, compared to a net outflow of CNY -334,560,867.47 in the prior period[24] - The cash and cash equivalents at the end of the period amounted to CNY 1,192,026,314.82, down from CNY 3,061,640,897.17 in the previous period[24] - Total assets at the end of the reporting period were ¥19,292,906,254.99, an increase of 1.77% from ¥18,958,118,495.62 at the end of the previous year[4] - Total liabilities are ¥11,703,412,302.31, slightly down from ¥11,712,850,544.99 in the previous period[20] - Non-current liabilities total ¥7,072,833,657.16, an increase from ¥6,432,438,826.25 in the previous period[20] - The company's equity attributable to shareholders increased by 1.47% to ¥6,715,556,070.81 from ¥6,618,401,890.60 at the end of the previous year[4] - Cash and cash equivalents increased to ¥3,526,773,637.00 from ¥2,332,286,827.44, reflecting a growth of 51.2%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,298[13] - The largest shareholder, Guangzhou High-tech Zone Modern Energy Group Co., Ltd., holds 43.89% of the shares, totaling 457,114,910 shares[13] - The company has repurchased a total of 9,597,000 shares, representing 0.92% of the total share capital, with a total expenditure of RMB 59,766,205.00[16] - The company has proposed a share repurchase plan with a budget between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 8 per share[16] Investment and Subsidiaries - The company plans to sell a 40% stake in Guangzhou Hengyun Dongqu Natural Gas Power Co., Ltd. for RMB 320,400,000 and a 51% stake in Guangzhou Baiyun Hengyun Energy Co., Ltd. for RMB 5,100,000 to introduce strategic investors[15] - The company will no longer consolidate Guangzhou Baiyun Hengyun Energy Co., Ltd. in its financial statements after the stake sale, reducing its ownership to 49%[15] - The company experienced a 67.17% increase in investment income, attributed to the transfer of equity in its subsidiary and increased investment income from joint ventures[8] - The company reported a 100.00% increase in cash received from the transfer of equity in subsidiaries, primarily from the sale of its stake in the subsidiary[10] Other Financial Metrics - The company reported a 360.85% increase in credit impairment losses, primarily due to an increase in bad debt provisions[8] - The company incurred a credit impairment loss of CNY -3,379,586.71, compared to a gain of CNY 1,295,586.33 in the previous period[22] - Total operating costs for the current period are ¥1,022,179,537.55, down 10.7% from ¥1,145,429,251.93 in the previous period[21] - Operating costs include ¥870,353,463.55 in operating expenses, which decreased by 11.3% from ¥981,341,704.16[21] - Research and development expenses for the current period are ¥21,080,721.09, a decrease of 24.0% from ¥27,721,001.30 in the previous period[21] - The accounts receivable increased to RMB 579,423,558.65 from RMB 441,957,561.93 at the beginning of the period, indicating a growth of approximately 31.2%[18] - The company’s inventory as of March 31, 2025, is valued at RMB 170,852,933.71, compared to RMB 160,457,734.77 at the beginning of the period[18] - The company’s other receivables have significantly increased to RMB 946,274,442.01 from RMB 46,529,445.53 at the beginning of the period[18]

证券代码：001309 证券简称：德明利 公告编号：2025-037 深圳市德明利技术股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 深圳市德明利技术股份有限公司 2025 年第一季度报告 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 深圳市德明利技术股份有限公司 2025 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 其他符合非经常性损益定义的损益项目的具体情况 □适用 不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益 项目的情况说明 □是 否 | | 本报告期 | ...